Noni Safety: Liver Case Reports, Potassium and Interactions

This is the most important page in this section, and it is the one most often left out entirely. Noni juice is sold as a gentle fruit product, and for most healthy adults drinking a modest daily amount that is probably a fair description. But two documented hazards have been published in mainstream medical journals, and neither appears on a bottle: a series of acute hepatitis case reports from several independent European centres, and a high potassium content that has caused hyperkalaemia in a patient with impaired kidney function.

Neither of the two easy positions is honest. "Noni destroys your liver" overstates a small number of idiosyncratic cases against a very large number of uneventful consumers. Silence about them, which is what most noni pages offer, withholds the one piece of information that could actually change an outcome. This page gives both sides of the liver argument in full, states plainly what European regulators concluded, and then sets out the potassium problem, the drug interactions, and the warning signs that mean stop today.

If you read nothing else, read this. Do not drink noni juice if you have any liver disease, a history of drug-induced liver injury, chronic kidney disease or dialysis, or hyperkalaemia from any cause; or if you are pregnant or breastfeeding. Ask a doctor or pharmacist first if you take an ACE inhibitor, an ARB, a potassium-sparing diuretic, trimethoprim, a potassium supplement, warfarin, methotrexate, or any other medication that stresses the liver. Stop immediately and get liver tests if you develop yellow eyes or skin, dark urine, pale stools, itching, right-upper-abdominal pain, or unexplained nausea and fatigue.

The Published Liver Case Reports
What the Injury Looked Like
The Manufacturer's Rebuttal and the Animal Data
Weighing the Two Sides
What EFSA Actually Concluded
Who Must Not Drink It: Liver
Warning Signs and What to Do
Potassium: The Concrete Hazard
Who Is at Risk from the Potassium
Drug Interactions
Pregnancy, Breastfeeding and Children
What Is Actually in the Bottle
Monitoring, Surgery and Sensible Limits
Putting the Risk in Proportion
Key Research Papers
Connections

The Published Liver Case Reports

These reports come from mainstream hepatology and gastroenterology journals, not from advocacy publications, and from several independent centres. That independence matters: a single case from a single group is anecdote, while consistent reports from unrelated hospitals are a signal.

Millonig, Stadlmann and Vogel, European Journal of Gastroenterology & Hepatology, 2005 — "Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia)". The index case in the literature. Find on PubMed.
Stadlbauer and colleagues, World Journal of Gastroenterology, 2005 — "Hepatotoxicity of NONI juice: report of two cases", from the hepatology unit in Graz, with liver biopsy findings and severe injury in one patient. Find on PubMed.
Yüce, Gülberg, Diebold and Gerbes, Digestion, 2006 — "Hepatitis induced by Noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg?", from Munich. The question in that title has never been settled, and it is the right question. Find on PubMed.
A further report from the Graz group in the American Journal of Gastroenterology in 2008, whose title makes the general point that "herbal" does not mean innocuous, adding another noni-associated case to the series. Find on PubMed.
Additional cases have been described from other European centres, and noni appears in reviews of herb-induced liver injury and in national supplement-safety reporting. PubMed topic search.

Because published case reports are how idiosyncratic drug injury is discovered in the first place, "it is only case reports" is not the dismissal it sounds like. Rare unpredictable liver injury cannot be found any other way — it is invisible to trials of the size any supplement ever receives.

What the Injury Looked Like

The clinical picture across the reported cases is broadly consistent, which is itself part of the evidence:

Pattern: hepatocellular — that is, injury to liver cells rather than to bile flow — with markedly raised transaminases (ALT and AST).
Symptoms: jaundice, dark urine, fatigue, nausea, poor appetite, sometimes itching and right-upper-abdominal discomfort.
Timing: weeks to a few months into regular daily consumption. Not first-dose, which is typical of idiosyncratic rather than dose-dependent toxicity.
Course: improvement after stopping the juice in most cases, which is the expected behaviour of drug-induced liver injury.
Rechallenge: in the published series, injury recurred in at least one patient who resumed noni. A positive rechallenge is among the strongest available evidence that a substance is genuinely causing the injury rather than being an innocent bystander — and it is not something anyone should do deliberately.
Severity range: from moderate biochemical hepatitis to severe injury assessed in a transplant context. Most reported patients recovered.
Candidate mechanism: the fruit's anthraquinones — morindone, damnacanthal, rubiadin and relatives, a compound class with recognised hepatotoxic and genotoxic members. Anthraquinones are far more concentrated in root and bark than in fruit, which is why contamination of fruit products with leaf or root material is a specific regulatory concern. PubMed topic search.

The Manufacturer's Rebuttal and the Animal Data

Fairness requires giving the other side properly, because it consists of real published data and not merely of denial.

West, Jensen and Westendorf, World Journal of Gastroenterology, 2006 — "Noni juice is not hepatotoxic", a direct response to the case reports, arguing that the reported cases had alternative explanations and that the exposure figures make a causal link implausible. Find on PubMed.
West, Su and Jensen, The Journal of Toxicological Sciences, 2009 — hepatotoxicity and subchronic toxicity testing of noni fruit in animals, reporting no liver injury at high doses. Find on PubMed.
The exposure argument is genuinely strong on its own terms: noni juice has been consumed by very large numbers of people over three decades, and the published case count is small.
The confounding argument is also fair: several reported patients were taking other medications or supplements, alcohol history is not always fully characterised, and commercial noni is a blend whose other components and possible contaminants are not always identified.

What to do with the authorship. The authors of both papers were affiliated with the principal noni manufacturer, and that is disclosed in the papers. Disclosure is how science is supposed to work, and industry-funded toxicology is often the only toxicology that exists. But a manufacturer publishing a paper titled "Noni juice is not hepatotoxic" in response to independent clinicians reporting hepatitis is not a neutral referee, and a reader is entitled to weigh that. Read both sets of papers; do not read only one.

Weighing the Two Sides

Put plainly, the arguments line up like this.

Pointing toward causation:

Multiple independent centres in different countries.
A consistent hepatocellular pattern across cases.
Improvement on withdrawal.
At least one positive rechallenge in the published series.
A plausible mechanism in a compound class known to contain hepatotoxins.

Pointing away from a simple causal story:

A small number of cases against very large population exposure.
Concomitant medications and supplements in several patients.
Product heterogeneity — the "noni juice" in each case was a different blend.
Negative animal toxicology at high doses.

The resolution that fits both sets of facts is idiosyncratic drug-induced liver injury: rare, unpredictable, not dose-proportional, dependent on individual susceptibility, and impossible to identify in advance. That is exactly the profile that produces a handful of severe cases amid millions of uneventful ones, and exactly the profile that negative animal studies cannot exclude, because the mechanism is host-dependent rather than intrinsic to the compound. Formal causality-assessment tools such as RUCAM exist precisely for this problem. PubMed topic search.

Evidence tier: documented harm. Not proven for any individual, and not excluded by the negative animal data.

What EFSA Actually Concluded

"EU-approved" appears constantly in noni marketing and is routinely misrepresented, so here is the accurate version.

Noni juice was assessed under the European Union's Novel Food framework and authorised for sale in 2003. After the hepatitis case reports appeared, the European Food Safety Authority was asked to look again, and its panel reviewed the reports and the available toxicological and consumption data. In substance, EFSA concluded that noni juice was not expected to cause adverse liver effects in the general population at the levels of intake it assessed, while explicitly acknowledging the published case reports and the possibility that particular individuals may react idiosyncratically. Separate opinions have also addressed noni fruit purée, noni powder and noni leaves. The authorisations were generally maintained.

What that means:

It is a food safety judgement about a specific product at specific intakes — the applicant demonstrated the food is safe under the proposed conditions of use.
It is not a finding that noni does anything therapeutic. EU health claims go through an entirely separate and far stricter process, and noni carries no authorised disease-treatment claim.
It is not a clearance for everyone. Safety assessments are made for the general healthy population. They do not clear a product for people with liver disease or kidney failure — the two groups this page is most concerned with.
It does not cover every product on sale. Concentrated extracts, capsules, leaf preparations and blends may fall outside a given authorisation.
The case reports were not retracted, and regulators did not say they were wrong. They judged that a food many people drink uneventfully should not be withdrawn because of rare idiosyncratic reactions — a defensible regulatory decision, and a different statement from "noni is safe".

Read the opinions yourself rather than a marketing summary of them: they are public at the European Food Safety Authority.

Who Must Not Drink It: Liver

Idiosyncratic injury cannot be predicted, so the sensible approach is to avoid adding an unpredictable hepatic risk to a liver that already has a problem or is already under load.

Do not drink noni if you have:

Chronic hepatitis B or hepatitis C — see Hepatitis Panel.
Fatty liver disease, including metabolic and alcohol-related forms — see Fatty Liver Disease.
Cirrhosis of any cause — see Liver Cirrhosis and Cirrhosis. In cirrhosis this is doubly important, because advanced liver disease also impairs potassium handling.
Autoimmune hepatitis — see Autoimmune Hepatitis. Two reasons apply at once here: the liver signal, and the fact that noni is marketed as an immune stimulant.
Alcohol-related liver disease, or a heavy drinking history — see Alcoholic Hepatitis.
Any previous drug- or supplement-induced liver injury. Somebody who has already reacted to one agent is the wrong person to test another on.
Unexplained abnormal liver tests that have not yet been worked up.
A liver transplant, or assessment for one.

Also avoid if you take a hepatically-loading medication: methotrexate, isoniazid, amiodarone, regular high-dose paracetamol/acetaminophen (see Acetaminophen Overdose), some antifungals, some antiretrovirals, and statins if your liver tests are already borderline. The principle is simple: do not stack an unpredictable hepatotoxin on top of a predictable one.

Warning Signs and What to Do

Stop noni immediately and arrange medical assessment including liver function tests if any of these appear:

Yellowing of the eyes or skin (jaundice) — the clearest single sign.
Dark urine, the colour of tea or cola, particularly with pale or clay-coloured stools.
Itching without a rash, often worst on the palms and soles.
Pain or fullness under the right ribs.
Nausea, loss of appetite or vomiting that is new and unexplained.
Unexplained fatigue that is worsening — treacherous here, because fatigue is often the reason people started noni in the first place. Worsening fatigue on noni is a reason to stop and test, never to increase the dose.
Easy bruising, confusion or swelling — these suggest significant liver dysfunction and mean urgent assessment.

What to ask for: a liver function panel (ALT, AST, alkaline phosphatase, bilirubin, albumin), GGT, and clotting studies if there is jaundice. A comprehensive metabolic panel covers most of this plus potassium and kidney function in one draw.

And tell the clinician about the noni, explicitly. Herbal and dietary supplements are a leading cause of otherwise unexplained abnormal liver tests, and the diagnosis is routinely missed because nobody asks and nobody volunteers. Take the bottle with you; the ingredient list matters.

Potassium: The Concrete Hazard

This risk gets less attention than the liver signal, is far easier to predict, and in the wrong person is more immediately dangerous. Severe hyperkalaemia is one of the few electrolyte problems that can kill within hours.

Noni juice is high in potassium. Mueller, Scott, Sowinski and Prag reported in the American Journal of Kidney Diseases in 2000, under the title "Noni juice (Morinda citrifolia): hidden potential for hyperkalemia?", that measured potassium in commercial noni juice was comparable with recognised high-potassium juices such as orange and tomato juice, and described a patient with chronic kidney disease who developed hyperkalaemia in association with drinking it. Find on PubMed.

Why this matters physiologically. Healthy kidneys excrete surplus potassium effortlessly, and dietary potassium is genuinely good for most people — it is actively encouraged for blood pressure. In chronic kidney disease, especially advanced stages or dialysis, the kidney cannot dump the excess. Serum potassium climbs, and above roughly 6.0–6.5 mmol/L it interferes with cardiac conduction: bradycardia, widening of the QRS complex, and ultimately cardiac arrest. Early symptoms are vague — muscle weakness, fatigue, nausea, tingling — which is precisely the problem, because they resemble the complaints the juice was bought to treat. See Potassium Toxicity, Muscle Weakness, Numbness and Tingling and Heart Palpitations and Arrhythmia.

Two aggravating details specific to noni products. First, powders and capsules concentrate potassium along with everything else, and the amount is essentially never declared. Second, potassium content is never on the front label and often absent from the nutrition panel entirely, so a renal patient counting potassium has no way to count this.

Who Is at Risk from the Potassium

Do not drink noni juice, in any amount, if you have:

Chronic kidney disease at any stage, and absolutely not in stages 4–5 or on dialysis. See Kidney Disease.
Acute kidney injury, or recovery from it — see Acute Kidney Injury.
Known hyperkalaemia from any cause.
Addison's disease or aldosterone deficiency, where potassium excretion is impaired hormonally.
Type 4 renal tubular acidosis, which occurs in poorly controlled diabetes and impairs potassium excretion — see Type 2 Diabetes and Diabetic Nephropathy.
Advanced cirrhosis, where potassium handling is also disturbed.
A kidney transplant — graft function plus calcineurin inhibitors is a high-risk combination for potassium.

Also at risk: anyone taking a drug that raises potassium.

ACE inhibitors — ramipril, lisinopril, enalapril, perindopril.
ARBs — losartan, candesartan, valsartan, irbesartan.
Potassium-sparing diuretics and aldosterone blockers — spironolactone, eplerenone, amiloride.
Trimethoprim, including in co-trimoxazole.
NSAIDs — ibuprofen, naproxen, diclofenac. Particularly relevant because so many people take noni for pain alongside them.
Potassium supplements and potassium-based salt substitutes.
Heparin, ciclosporin and tacrolimus, all of which can raise potassium.

If you are on any of these and want to drink noni anyway, the minimum is to tell your prescriber and have your potassium and kidney function checked. A basic metabolic panel shows both. Practical guidance on potassium in the diet is at the National Kidney Foundation, and the underlying nutrient page here is Potassium.

Drug Interactions

Beyond the potassium and liver interactions above:

Warfarin and other anticoagulants. Noni contains coumarins, including scopoletin, and leaf material contains vitamin K. Reports of INR disturbance with noni exist. If you are anticoagulated, either avoid it or check your INR a week after starting and a week after stopping. PubMed topic search.
Antihypertensives. Possible additive blood-pressure lowering, and the ACE-inhibitor and ARB potassium problem sits here too. See Hypertension.
Antidiabetic medication. Animal work suggests glucose lowering, so additive effects are theoretically possible — while the added sugar in blended products pushes the other way. Monitor if you use insulin or a sulfonylurea.
Immunosuppressants. Noni polysaccharides are immunomodulatory in animal models, which is a theoretical opposition to ciclosporin, tacrolimus, azathioprine or a biologic. Transplant recipients are also the group in whom liver, kidney and potassium are watched most closely.
Diuretics generally. Loop and thiazide diuretics lower potassium, potassium-sparing ones raise it; adding an uncounted potassium load to either makes the balance harder to manage.
Chemotherapy and radiotherapy. Tell your oncology team about any supplement. Beyond interaction risk, noni's hepatic signal is unwelcome alongside hepatically-metabolised cytotoxics. See Oncology.
Lithium. Anything that alters fluid balance or kidney handling deserves caution; check levels if starting or stopping.

Pregnancy, Breastfeeding and Children

Pregnancy: avoid. Noni root and fruit carry traditional reputations as emmenagogues and abortifacients in several Pacific and Southeast Asian traditions. Whether that pharmacology is real is unknown; there is no adequate human safety data either way, and a traditional abortifacient reputation is not something to test during a pregnancy. Traditional-use warning plus absent safety data.
Breastfeeding: avoid. No data on transfer into milk or infant effects.
Children: avoid. No paediatric safety or dosing data. Children have a smaller volume of distribution, so a potassium load and any hepatic exposure count for more, and idiosyncratic liver injury in a child is a catastrophic outcome to risk for a product with no demonstrated benefit.
Older adults deserve a specific note. Kidney function declines with age, often without symptoms and often without anyone having measured it, and older adults are more likely to be on an ACE inhibitor, ARB, diuretic or NSAID. That combination — unrecognised reduced clearance plus potassium-raising drugs plus an uncounted potassium load — is the recipe for the case report.

What Is Actually in the Bottle

The formulation reality is a safety issue, not just a value-for-money one.

Blending. Ripe noni is bitter and smells of ripe cheese, so commercial products are commonly cut with grape, apple, blueberry or pear juice and often sweetened. A bottle labelled "noni juice" may be a minority noni by volume. Read the ingredient list; components are listed by weight.
Consequence for dose. If a study used pure fermented juice and your bottle is one-fifth noni, the millilitres on the label mean something different. Claimed doses are not comparable between products.
Consequence for sugar. Grape juice is among the highest-sugar fruit juices. A daily sweetened juice is a poor trade for anyone with diabetes, prediabetes or fatty liver disease — and fatty liver disease is itself a reason not to take noni at all.
Consequence for potassium. Blending changes the potassium content in ways the label will not tell you, and the added juices are frequently high-potassium themselves.
Product variability is documented. Potterat and colleagues, in the Journal of Agricultural and Food Chemistry in 2007, quantified constituents across noni powders and commercial products and showed how widely they differ — independent work, and the most useful consumer paper in the field. Find on PubMed.
Fruit, leaf and root are different products with different chemistry and different regulatory assessments. Root has the highest anthraquinone content and is a dye material, not a supplement.
What to look for: the actual noni percentage, whether it is fruit or leaf, iridoid or DAA standardisation, added sugars, and a manufacturer that publishes testing. What you will not see, and should mentally add, is the potassium.

Monitoring, Surgery and Sensible Limits

If, having read all of the above, none of the exclusions apply and you choose to drink noni:

Stay at or below the label dose — commonly 30–60 ml daily. Ignore "loading phase" advice; there is no evidence for it and it raises both the potassium load and hepatic exposure.
Treat it as a food, not a medicine. It has no established therapeutic dose because it has no established indication.
Do not take it open-endedly for months without occasional liver tests, particularly alongside other medication. The reported cases clustered at weeks to months of daily use.
Count it as a potassium-containing juice if potassium matters for you at all.
Stop two weeks before surgery, as with most supplements — the theoretical anticoagulant and blood-pressure effects, and the general principle of not confounding perioperative liver tests.
Stop at once for any of the warning signs above.
Add it to your medication list so it appears in your record and any clinician can see it.

Common minor effects, for completeness: the smell and taste cause nausea in some people, loose stools are reported, and the juice is acidic enough to aggravate reflux.

Putting the Risk in Proportion

Overstating this would be as much of a failure as omitting it, so here is the balanced statement.

For a healthy adult with normal liver and kidney function, on no interacting medication, drinking a modest daily amount of a blended noni juice, the absolute risk of serious harm appears low. Many millions of doses have been consumed and the published case series is small. That is a real fact and it belongs here.

But the risk-benefit arithmetic is unusual for noni, and it is what should decide the question. On the benefit side, as the pain, immune and energy pages set out, there is no established indication at all — not one condition for which noni has been shown to work in adequate human trials. On the risk side there is a documented, if rare, liver signal and a fully predictable potassium hazard. A small risk against an unproven benefit is a poor trade even when the risk is genuinely small.

And for two groups the arithmetic is not close. If you have liver disease, or chronic kidney disease, or you take a potassium-raising drug, noni is a bad idea, and the fact that most people drink it uneventfully is irrelevant to you. That asymmetry — near-zero demonstrated benefit for everyone, real hazard for identifiable groups — is the whole point of this page.

Key Research Papers

References are given as PubMed searches rather than numeric identifiers, so that you land on the live record for the paper rather than on a mistyped ID. Where a figure or exact detail is not certain, the finding is described rather than asserted.

Millonig, Stadlmann and Vogel. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). European Journal of Gastroenterology & Hepatology, 2005. The index case. PubMed.
Stadlbauer and colleagues. Hepatotoxicity of NONI juice: report of two cases. World Journal of Gastroenterology, 2005. With biopsy findings. PubMed.
Yüce, Gülberg, Diebold and Gerbes. Hepatitis induced by Noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg? Digestion, 2006. PubMed.
Stadlbauer and colleagues. A further noni-associated hepatotoxicity case, arguing that "herbal" does not mean innocuous. American Journal of Gastroenterology, 2008. PubMed.
West, Jensen and Westendorf. Noni juice is not hepatotoxic. World Journal of Gastroenterology, 2006. The manufacturer-affiliated rebuttal — read alongside items 1–4. PubMed.
West, Su and Jensen. Hepatotoxicity and subchronic toxicity tests of Morinda citrifolia (noni) fruit. The Journal of Toxicological Sciences, 2009. PubMed. Animal, industry-affiliated.
Mueller, Scott, Sowinski and Prag. Noni juice (Morinda citrifolia): hidden potential for hyperkalemia? American Journal of Kidney Diseases, 2000. The potassium paper, and the most actionable citation on this page. PubMed.
Potterat and colleagues. Identification of markers and quantification of constituents in noni fruit powder and commercial noni-derived products. Journal of Agricultural and Food Chemistry, 2007. Independent evidence of product variability. PubMed.
Wang and colleagues. Morinda citrifolia (Noni): a literature review and recent advances in Noni research. Acta Pharmacologica Sinica, 2002. The field's most-cited review; manufacturer-affiliated authorship. PubMed.

Live PubMed Searches

External Resources

European Food Safety Authority — the actual novel-food opinions on noni juice, purée, powder and leaves. Read these rather than summaries of them.
LiverTox (NIH/NIDDK) — the free reference on drug- and herb-induced liver injury, and the right place to check any supplement before long-term use.
National Kidney Foundation — potassium and diet in kidney disease.
NIH National Center for Complementary and Integrative Health — plain-language botanical safety summaries.
MedlinePlus — NIH consumer information on the drugs named above.

Connections

Safety note and disclaimer. This article is health education, not medical advice, and it cannot substitute for assessment by a clinician who knows your history and medications. Noni has no established therapeutic indication and should never replace treatment that works. Do not take noni if you have liver disease, a history of drug- or supplement-induced liver injury, chronic kidney disease, acute kidney injury, hyperkalaemia, or during pregnancy or breastfeeding, and do not give it to children. Speak to your doctor or pharmacist before combining it with ACE inhibitors, ARBs, potassium-sparing diuretics, trimethoprim, potassium supplements or salt substitutes, NSAIDs, warfarin, methotrexate, immunosuppressants or any hepatotoxic medication. Stop immediately and seek medical assessment including liver function tests if you develop jaundice, dark urine, pale stools, itching, right-upper-abdominal pain, or unexplained nausea and fatigue. Seek urgent care for palpitations, severe muscle weakness or collapse, which can signal hyperkalaemia.

Back to Table of Contents